Heart failure is a complex clinical syndrome caused by structural and/or functional cardiac abnormalities. Ventricular remodeling contributes to its progression. Cardiac macrophages regulate inflammation, fibrosis, and tissue repair that drive this process. In this Review, we describe the origins and phenotypic diversity of cardiac macrophages, including both resident and monocyte-derived subsets. In the left ventricle, macrophages respond to ischemia, pressure overload, and metabolic stress. In the right ventricle, they display distinct immune features under pulmonary hypertension and other stress conditions. We further discuss the interactions between macrophages and other cardiac cell types, such as fibroblasts, cardiomyocytes, endothelial cells, and lymphocytes. These interactions shape the immune environment and structural integrity of the myocardium. We also highlight recent advances in single-cell and spatial technologies that reveal chamber-specific macrophage signatures. Finally, we summarize emerging therapeutic strategies targeting macrophages, including pharmacological agents, engineered cell therapies, and nanoparticle-based delivery systems. Together, these insights provide a framework for understanding macrophage-mediated remodeling and for guiding precision immunotherapies in heart failure.
Background: The elderly with severe infection increased dramatically in intensive care unit (ICU). Proper antimicrobial therapy help improve the prognosis. Linezolid, as an antimicrobial drug, is commonly utilized to treat patients infected with methicillin-resistant S. aureus and vancomycin-resistant enterococci. Clinical evidence suggests elderly patients prone to linezolid overexposure. Here, we describe the results of three years’ linezolid adjustment experiences according to therapeutic drug monitoring (TDM), especially in the oldest old. Methods: Linezolid therapeutic drug monitoring data were collected between January 2020 and November 2022 from patients who were admitted to ICU and treated with linezolid. All the patients started with a dosage of 600 mg, twice daily. The first TMD was carried out ten minutes before the seventh administration. The dosage adjustment was determined by the doctor according to the first TMD and patients' condition, and the repeated TDM was conducted as required. The dosage adjustment in different age group was recorded. Laboratory data were compared between the old and the oldest old. The high mortality risk of the oldest old was also explored. Results: Data of 556 linezolid TDM from 330 patients were collected. Among which, 31.6%, 54.8%, and 75% of patients had supra-therapeutic linezolid trough concentrations at the first TDM assessment in different age group, leading to the dosage adjustment rate of 31.0%, 40.3%, 68.8% respectively. The linezolid dosage adjustments according to TDM help to reach therapeutic concentration. The oldest old was in high risk of linezolid overexposure with lowercreatinine clearance. The norepinephrine maximum dosage but not linezolid Cmin was associated with 28-day mortality in the oldest old. Conclusions: Elderly patients with linezolid conventional 600 mg twice-daily dose might be at a high risk of overexposure, especially in the oldest old. The linezolid dosage adjustments according to TDM help reach the therapeutic concentration. The high mortality of the oldest old was not related with initial linezolid overexposure.
13 January 2025 in Biological Trace Element Research
Several studies have reported associations between specific heavy metals and essential trace elements and acute myocardial infarction (AMI). However, there is limited understanding of the relationships between trace elements and AMI in real-life co-exposure scenarios, where multiple elements may interact simultaneously. This cross-sectional study measured serum levels of 56 trace elements using inductively coupled plasma mass spectrometry. We identified individual trace elements linked to AMI using four feature selection methods and evaluated their associations with AMI prevalence and severity through multiple-element logistic regression. Restricted cubic spline analysis was employed to examine non-linear associations. Additionally, we explored the associations between trace element mixtures and AMI prevalence and severity using Bayesian kernel machine regression (BKMR) and element risk score (ERS). Finally, we investigated the potential mechanisms linking trace element exposure to AMI. We detected stable positive associations and linear relationships between Cu and Rb and AMI prevalence and severity. Furthermore, lower Fe concentrations were associated with higher AMI prevalence, while higher Sb concentrations were linked to greater AMI severity. Both BKMR and ERS models indicated positive associations between trace element mixtures and AMI prevalence and severity. Mediation analysis suggested that high-sensitivity C-reactive protein partially mediated the associations between trace elements and AMI prevalence and severity. We provide the first epidemiological evidence of the associations between serum trace element mixtures and AMI prevalence and severity. Under conditions of trace element co-exposure, Cu, Rb, Fe, and Sb were closely associated with AMI. Additionally, our results indicate that hsCRP (inflammation) may be a potential mechanism linking trace elements to AMI.
5 February 2025 in Human Vaccines & Immunotherapeutics
Cholesteryl ester transfer protein (CETP) plays a key role in lipoprotein metabolism, and its activity has been linked to the risk of atherosclerosis (AS). CETP inhibitors, such as obicetrapib, represent a novel approach in immunotherapy to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) by targeting lipid metabolism. In addition, CETP vaccines are being explored as a novel strategy for the prevention and treatment of ASCVD by inducing the body to produce antibodies against CETP, which is expected to reduce CETP activity, thereby increasing high-density lipoproteins (HDL) levels. This paper provides a comprehensive overview of the structure of CETP, the mechanisms of lipid transfer and the progress of immunotherapy in the last decade, which provides possible ideas for future development of novel drugs and optimization of immunization strategies.
Background: Sarcopenia and osteoporosis are interrelated conditions that significantly contribute to adverse health outcomes. Both conditions are negatively influenced by oxidative stress. While antioxidant supplementation has been explored as a potential intervention, its efficacy remains inconsistent, highlighting the complexity of oxidative stress management. The oxidative balance score (OBS) is a novel metric that evaluates the interplay between pro-oxidants and antioxidants, providing a holistic assessment of the body’s oxidative status. Despite its promise, the relationship between OBS and osteosarcopenia—a coexistence of sarcopenia and osteoporosis—has not been extensively studied.Methods: Data from the National Health and Nutrition Examination Survey, a national cross-sectional study. The association between OBS and osteosarcopenia was evaluated using weighted logistic regression, restricted cubic spline, and receiver operating characteristic curve analyses. Subgroup analyses were conducted to explore potential population differences. Additionally, we examined the relationships between dietary and lifestyle OBS and osteosarcopenia separately.Results: The study included 3,336 adults (mean age: 43.30 ± 13.73 years; 53.15% males) with complete data on muscle mass and bone mineral density. OBS was linearly and negatively associated with osteosarcopenia and effectively differentiated individuals with osteosarcopenia from healthy individuals. No significant interactions were observed in the subgroup analyses. Lifestyle OBS showed a stronger association with osteosarcopenia compared to dietary OBS.Conclusion: OBS is inversely associated with the prevalence of osteosarcopenia, indicating that individuals with higher OBS tend to have a lower likelihood of osteosarcopenia. Moreover, OBS demonstrates good discriminative ability, effectively identifying individuals who are more likely to have osteosarcopenia from healthy individuals.
Introduction: Cardiac aging is the major risk factor for advanced heart disease, which is the leading cause of death in developed countries, accounting for >30% of deaths worldwide. Objective: To discover the detailed mechanism of cardiac aging and develop an effective therapeutic candidate drug to treat or delay cardiac aging. Methods: We used D-galactose to induce cardiac aging in Nrf2+/+ and Nrf2–/– mice, and then treated these mice with vehicle or the Nrf2 activator, CDDO-imidazolide (CDDO-Im). Results and Conclusions: D-galactose injection significantly induced cardiac aging, cell apoptosis, and oxidative stress in Nrf2+/+ mice, all of which were further exacerbated in Nrf2–/– mice. CDDO-Im treatment can effectively weaken oxidative stress and enhance the activities of antioxidant enzymes, but CDDO-Im lost its antioxidative effect in the Nrf2–/– mice. Nrf2 activator CDDO-Im could therefore effectively protect against D-galactose-induced cardiac aging by inhibiting oxidative stress, suggesting that CDDO-Im might be a potential and promising therapeutic candidate drug to treat cardiac aging.